Compare Morgan Stanley (MS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Novo Nordisk A/S — how do they compare? Morgan Stanley trades at $215.61 (market cap $339.62B), while Novo Nordisk A/S trades at $44.69 (market cap $200.69B). The key difference: Morgan Stanley is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| MS | NVO | |
|---|---|---|
Market Cap | $339.62B | $200.69B |
Sector | Financials | Health |
52-Week High | $228.42 | $63.98 |
52-Week Low | $151.86 | $35.29 |
Dividend Yield | 2.13% | 3.98% |
Enterprise Value | — | $215.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.33, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $239.58. Revenue grew to $66.0 billion in 2025, with net income margin expanding to 25.56%, and the company has beaten EPS estimates in recent quarters. Recent news highlights its role in leading Anthropic's IPO and advancements in AI integration for wealth management.
The outlook remains positive given strong earnings momentum and strategic initiatives, though risks include volatile cash flows from operations and high leverage. Wall Street sentiment is bullish with 55.77% of analysts rating it a Buy, supporting potential upside from current levels amid broader financial sector strength.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
